Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
06 2019
Historique:
received: 02 07 2018
revised: 21 10 2018
accepted: 29 10 2018
pubmed: 21 11 2018
medline: 8 5 2020
entrez: 21 11 2018
Statut: ppublish

Résumé

Grip strength is a well-characterised measure of weakness and of poor muscle performance, but there is a lack of consensus on its prognostic implications in terms of cardiac adverse events in patients with cardiac disorders. Articles were searched in PubMed, Cochrane Library, BioMed Central and EMBASE. The main inclusion criteria were patients with cardiac disorders (ischaemic heart disease, heart failure (HF), cardiomyopathies, valvulopathies, arrhythmias); evaluation of grip strength by handheld dynamometer; and relation between grip strength and outcomes. The endpoints of the study were cardiac death, all-cause mortality, hospital admission for HF, cerebrovascular accident (CVA) and myocardial infarction (MI). Data of interest were retrieved from the articles and after contact with authors, and then pooled in an individual patient meta-analysis. Univariate and multivariate logistic regression was performed to define predictors of outcomes. Overall, 23 480 patients were included from 7 studies. The mean age was 62.3±6.9 years and 70% were male. The mean follow-up was 2.82±1.7 years. After multivariate analysis grip strength (difference of 5 kg, 5× kg) emerged as an independent predictor of cardiac death (OR 0.84, 95% CI 0.79 to 0.89, p<0.0001), all-cause death (OR 0.87, 95% CI 0.85 to 0.89, p<0.0001) and hospital admission for HF (OR 0.88, 95% CI 0.84 to 0.92, p<0.0001). On the contrary, we did not find any relationship between grip strength and occurrence of MI or CVA. In patients with cardiac disorders, grip strength predicted cardiac death, all-cause death and hospital admission for HF. CRD42015025280.

Identifiants

pubmed: 30455175
pii: heartjnl-2018-313816
doi: 10.1136/heartjnl-2018-313816
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

834-841

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Rita Pavasini (R)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.

Matteo Serenelli (M)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.

Carlos A Celis-Morales (CA)

BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Stuart R Gray (SR)

BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Kazuhiro P Izawa (KP)

Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Satoshi Watanabe (S)

Department of Rehabilitation Medicine, St Marianna University School of Medicine Hospital, Sugao, Japan.

Eloisa Colin-Ramirez (E)

National Council for Science and Technology (CONACyT) - Sociomedical Research Department, Instituto Nacional de Cardiología 'Ignacio Chávez', Mexico City, Mexico.

Lilia Castillo-Martínez (L)

Clinical Nutrition Department, Instituto Nacional de Ciencias Médicas y Nutrición SZ, Mexico City, Mexico.

Yasuhiro Izumiya (Y)

Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Shinsuke Hanatani (S)

Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Yoshiro Onoue (Y)

Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Kenichi Tsujita (K)

Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Peter S Macdonald (PS)

Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

Sunita R Jha (SR)

Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

Véronique L Roger (VL)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Sheila M Manemann (SM)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

Juan Sanchis (J)

Cardiology Department, Hospital Clinico Universitario, INCLIVA, Valencia, Spain.
Department of Medicine, University of Valencia, CIBER-CV, Valencia, Spain.

Vicente Ruiz (V)

Nursing School, University of Valencia, Valencia, Spain.

Giulia Bugani (G)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.

Elisabetta Tonet (E)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.

Roberto Ferrari (R)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.
GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy.

Stefano Volpato (S)

Department of Medical Science, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Ferrara, Italy.

Gianluca Campo (G)

Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.
GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH